India News | Bharat Biotech Complete Enrollment of 25,800 Volunteers for Covaxin Phase-3 Trials
Get latest articles and stories on India at LatestLY. Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3 trials of its COVID-19 vaccine Covaxin, Suchitra Ella, joint managing director, Bharat Biotech International Ltd said on Thursday.
Hyderabad, Jan 7 (PTI) Bharat Biotech has completed enrollment of 25,800 volunteers for the Phase-3 trials of its COVID-19 vaccine Covaxin, Suchitra Ella, joint managing director, Bharat Biotech International Ltd said on Thursday.
In a message posted on the company's Twitter account, she thanked clinical trial sites, principal investigators and health workers for their support and trust in the "public- private partnership" vaccine discovery.
"My deep appreciation to all the volunteers for reposing and expressing Pro Vaccine Public Health Voluntarism in the phase-3 clinical trials of India's 1st fully indigenous COVID-19 vaccine," she said referring to Covaxin.
The Drug Controller General of India (DCGI) has recently given Emergency Use Authorisation for Covaxin.
The Phase III human clinical trials of Covaxin began mid-November, targeted to be done in 26,000 volunteersacross India.
The company had said it is the only Phase-3 efficacy study for a COVID-19 vaccine, and the largest efficacy trial (Phase-3) ever conducted for any vaccine in India.PTI GDK SS
(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)